deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT02019264

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI)

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Sponsor: Eisai Inc.

Conditions Cardiovascular Disease High Cardiovascular Risk Obesity Overweight Type 2 Diabetes
Interventions Lorcaserin hydrochloride Placebo
Updated 13 times since 2017 Last updated: Jun 27, 2019 Started: Jan 24, 2014 Primary completion: May 14, 2018 Completion: May 14, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Cardiovascular Disease and High Cardiovascular Risk and is currently completed. Eisai Inc. leads this study, which shows 13 recorded versions since 2014 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Aug 2019 · 10 months · monthly snapshot~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE4

  3. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

▶ Show 8 earlier versions

  1. Aug 2019 — Jan 2021 [monthly]

    Completed PHASE4

  2. Oct 2018 — Aug 2019 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  3. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE4

  4. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE4

  5. Jun 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE4

  6. Mar 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE4

  7. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE4

  8. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE4

    First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eisai Inc.
  • The TIMI Study Group
Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Aguascalientes, Mexico , Albany, United States , Albuquerque, United States , Alexander City, United States , Alexandria, United States , Alhambra, United States , Alpena, United States , Altoona, United States , Anchorage, United States and 367 more locations